Accès ouvert
2024
article
OpenAlex
Saadettin Kılıçkap, Akın Öztürk, Nuri Karadurmuş, Taner Korkmaz et autres
To evaluate radiological and clinical features in metastatic anaplastic lymphoma kinase+ non-small cell lung cancer patients and crizotinib efficacy in different lines. This national, non-interventional, multicenter, retrospective archive screening study evaluated demographic, clinical, and radiological imaging features, and treatment approaches in patients …
tr, ch, us, gb, cn, br, bh, ee, Sénégal
(code pays fourni par la source)
Accès ouvert
2020
article
OpenAlex
İrfan Çiçin, Aydın Çiltaş, Saadettin Kılıçkap, Berna Öksüzoğlu et autres
ABS TRACT Objective:The study aimed to evaluate the efficacy of targeted therapies used as the third-line treatment after first-line cytokine and second-line tyrosine kinase inhibitor (TKI) therapies in metastatic renal cell carcinoma (mRCC) patients and assess the quality of life (QoL) of …
tr, gb
(code pays fourni par la source)
Accès ouvert
2019
conference-abstract
OpenAlex
Güray Saydam, Aslıhan Yürüktümen Ünal, Erdal Kurtoğlu, Mesut Göçer et autres
Background: Tyrosine kinase inhibitors (TKIs) have been standard‐of‐care for patients with chronic myeloid leukemia (CML) and improvements with TKIs have been obtained in survival rates. In Turkey, imatinib is the only reimbursed TKI for first line treatment and second generation TKI's are …
tr, gb
(code pays fourni par la source)